Silexion Therapeutics Corp announced significant new findings from its Phase 2 trial of LODER™ targeting non-resectable locally advanced pancreatic cancer. The updated analysis revealed a 56% objective response rate (ORR) for patients treated with LODER, with the ORR rising to 67% for those whose tumors became resectable post-treatment. The press release detailing these findings was issued on September 24, 2024.
Names and Titles: - Ilan Hadar: Chief Executive Officer of Silexion Therapeutics Corp